letters
Germline deletion of the miR-17~92 cluster causes skeletal and growth defects in humans
Loïc de Pontual1,2,10, Evelyn Yao3,10, Patrick Callier4, Laurence Faivre4, Valérie Drouin5, Sandra Cariou1, Arie Van Haeringen6, David Geneviève7, Alice Goldenberg5, Myriam Oufadem1, Sylvie Manouvrier8,
Arnold Munnich1,9, Joana Alves Vidigal3, Michel Vekemans1, Stanislas Lyonnet1,9, Alexandra Henrion-Caude1, Andrea Ventura3,10 & Jeanne Amiel1,9,10
MicroRNAs (miRNAs) are key regulators of gene expression in animals and plants. Studies in a variety of model organisms show that miRNAs modulate developmental processes. To our knowledge, the only hereditary condition known to be caused by a miRNA is a form of adult-onset non-syndromic deafness1, and no miRNA mutation has yet been found to be responsible for any developmental defect in humans. Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-17~92 polycistronic miRNA cluster, in individuals with microcephaly, short stature and digital abnormalities. We demonstrate that haploinsufficiency of miR-17~92 is responsible for these developmental
abnormalities by showing that mice harboring targeted deletion of the miR-17~92 cluster phenocopy several key features of the affected humans. These findings identify a regulatory function for miR-17~92 in growth and skeletal
development and represent the first example of an miRNA gene responsible for a syndromic developmental defect in humans.The MIR17HG locus encodes for miR-17~92, a polycistronic miRNA cluster from which six distinct miRNAs are produced (Supplementary Fig. 1). Genetic and functional studies have provided overwhelm-ing evidence that this cluster is a bona fide human oncogene2–10. In addition, loss-of-function experiments in mice have shown that miR-17~92 is essential for mammalian development and that its
11complete inactivation leads to perinatal lethality.
Feingold syndrome (MIM164280) is an autosomal dominant syn-drome whose core features are microcephaly, relative short stature and digital anomalies, particularly brachymesophalangy of the second and fifth fingers and brachysyndactyly of the toes12,13. Less penetrant defects include oesophageal, duodenal atresia (observed in 30–55% of cases), heart and kidney defects and variable learning disabilities. In approximately 70% of affected families, Feingold syndrome is caused
by germline loss-of-function mutations of MYCN (MIM164840) at 2p24.1 (refs. 14,15), but the genetic lesion(s) responsible for the remaining cases have yet to be identified.
We employed high-resolution comparative genomic hybridiza-tion (CGH) arrays to perform a genome-wide analysis of ten index subjects with skeletal abnormalities consistent with a diagnosis of Feingold syndrome but who lacked any mutation at the MYCN locus (Supplementary Table 1). This led to the identification of germline hemizygous microdeletions at 13q31.3 in two subjects (AO39 II3 and AO70 II1; Figs. 1 and 2a). The deletion in AO39 II3 spans 2.98 Mb and encompasses three genes: LOC144776, MIR17HG and GPC5 (Glypican-5). The deletion identified in AO70 II1 is more informative, as it spans 165 kb and encompasses only miR-17~92 and the first exon of GPC5 (Fig. 2a). Quantitative PCR (qPCR) and direct sequencing of MIR17HG (including the promoter region) and of the GPC5 coding sequence failed to identify non-annotated sequence variations in the remaining eight index subjects (data not shown, and the primers used are listed in Supplementary Table 2).
By genomic qPCR, we determined that the deletions detected in the two index subjects segregate with disease in the two families (Fig. 2b), thus lending support to the hypothesis that these two microdeletions are the causative mutations in these individuals. Next, we queried the Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources (DECIPHER) database, which contains array CGH data from more than 6,000 individuals with a variety of disorders16, and identified an additional individual (subject id: 248412) harboring a 180-kb hemizygous 13q31.3 microdeletion encompassing the entire MIR17HG locus and the first exon of GPC5 (Figs. 1 and 2a). This deletion was fur-ther confirmed by genomic qPCR (Fig. 2b). Unfortunately, because of the lack of any genetic and clinical data from the parents of this individual, it is unclear whether the deletion was inherited or was de novo. Although not classified as having Feingold syndrome, this
© 2011 Nature America, Inc. All rights reserved


.
1Unité INSERM U-781, Université Paris Descartes, Paris, France. 2Services de Pédiatrie, Hôpital Jean Verdier, Université Paris XIII, Assistance Publique-Hôpitaux
de Paris (AP-HP), Bondy, France. 3Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. 4Service de Génétique, Hôpital d’enfants, Dijon, France. 5Service de Génétique, Hôpital Charles Nicolle, Rouen, France. 6Department of Human and Clinical Genetics, Leiden University
Medical Center, Leiden, The Netherlands. 7Service de Génétique, Hôpital Arnaud de Villeneuve, Montpellier, France. 8Service de Génétique Clinique, Hôpital J. de Flandre, Lille, France. 9Services de Génétique et Cytogénétique, Hôpital Necker-Enfant Malades, AP-HP, Paris, France. 10These authors contributed equally to this work. Correspondence should be addressed to J.A. (jeanne.amiel@inserm.fr) or A.V. (venturaa@mskcc.org).

Received 12 April; accepted 29 July; published online 4 September 2011; doi:10.1038/ng.915
Nature GeNetics
热门文档